dyslipidemia
DYSLIPIDEMIA
Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.

Definition

  • An abnormality in lipoprotein metabolism that results in elevations of low-density lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides, and/or non-high-density lipoprotein cholesterol (non-HDL-C) levels, or significantly reduced high-density lipoprotein cholesterol (HDL-C) levels
  • Increase in serum concentration of total cholesterol, LDL, triglycerides or non-HDL-C is equivalent to increased risk for cardiovascular diseases

Etiology

  • Depends on the type of dyslipidemia
  • Hereditary disorders associated with dyslipidemia include familial hypercholesterolemia, familial hypertriglyceridemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia, chylomicronemia
  • Secondary causes include diabetes mellitus, diet, alcohol intake, hypothyroidism, renal failure, obstructive liver disease, Cushing’s syndrome, metabolic syndrome, medications (glucocorticoids, beta-blockers, thiazides, estrogen therapy)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 09 Aug 2019
Uric acid-lowering therapy for gout also confers benefits for hyperlipidaemia, with febuxostat delivering greater reductions in cholesterol and triglyceride concentrations in the blood as compared with allopurinol and benzbromarone, according to a recent study.
Roshini Claire Anthony, 08 Apr 2019

About one-third of individuals who achieved remission of type 2 diabetes (T2D) after losing weight with an intensive weight management programme sustained their remission at 2 years, according to long-term results of the DiRECT* trial.

31 Jul 2019
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
12 Aug 2019
Chronic exposure to higher cortisol levels among patients with Turner syndrome (TS) is linked to short stature and greater total cholesterol levels, according to a study. Cortisol exposure also contributes to an increase in cardiovascular disease risk.